There are currently 227 clinical trials in Santa Monica, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Citruslabs, Clinical Science Institute, Sarcoma Oncology Center and John Wayne Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
NCT04890613
Recruiting
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2024
Locations: University of California, Los Angeles, Santa Monica, California
Conditions: Advanced Solid Tumor
Register for Updates
ExoLuminate Study for Early Detection of Pancreatic Cancer
NCT05625529
Recruiting
ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, California
Conditions: Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Register for Updates
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
NCT05756907
Recruiting
This is a Phase 1b/2a, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian Cancer (Part 2)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2023
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Advanced Solid Tumor, Platinum-resistant Ovarian Cancer
Register for Updates
Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)
NCT03420014
Recruiting
The present study is an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic leiomyosarcoma patients.
Gender:
ALL
Ages:
Between 16 years and 100 years
Trial Updated:
10/06/2023
Locations: Sarcoma Oncology Research Center (SORC) Cancer Center of Southern California, Santa Monica, California
Conditions: Leiomyosarcoma
Register for Updates
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
NCT04759664
Recruiting
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: UCLA, Santa Monica, California
Conditions: EGFRI Induced Acneiform Lesions
Register for Updates
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT05485974
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Sarcoma Oncology, Santa Monica, California
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
Register for Updates
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Sarcoma Oncology, Santa Monica, California +1 locations
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Register for Updates
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT05708950
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: 1. What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? 2. What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: UCLA Health (Santa Monica Cancer Care), Santa Monica, California
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Register for Updates
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.
NCT05289466
Recruiting
Prospective, Non-randomized, Single-arm.The objectives of this study are to evaluate cosmesis and perioperative complications associated with the use of intraoperative radiotherapy (IORT) at the time of partial mastectomy in patients with breast cancer and a prior history of radiation therapy. Secondary objectives include evaluating effectiveness of partial mastectomy with IORT, measured by local, regional and distant recurrence, mastectomy rate, and disease-specific and overall survival.
Gender:
FEMALE
Ages:
50 years and above
Trial Updated:
04/10/2023
Locations: Providence Saint John's Hospital, Santa Monica, California
Conditions: IORT-Intra-Operative Radiation Therapy
Register for Updates
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
NCT04106492
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2023
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Cancer
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer
NCT05486143
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2022
Locations: UCLA Hematology/Oncology-Santa Monica, Santa Monica, California
Conditions: Breast Cancer
Register for Updates